Compare CRSP & MGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | MGY |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.2B |
| IPO Year | 2016 | 2017 |
| Metric | CRSP | MGY |
|---|---|---|
| Price | $46.38 | $31.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 13 |
| Target Price | ★ $70.29 | $28.17 |
| AVG Volume (30 Days) | 2.0M | ★ 2.7M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.15% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.24 |
| Revenue | $289,590,000.00 | ★ $1,311,845,000.00 |
| Revenue This Year | $1,082.59 | $0.70 |
| Revenue Next Year | $87.74 | $9.46 |
| P/E Ratio | ★ N/A | $127.81 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $30.06 | $19.09 |
| 52 Week High | $78.48 | $31.21 |
| Indicator | CRSP | MGY |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 78.62 |
| Support Level | N/A | $22.97 |
| Resistance Level | $60.63 | N/A |
| Average True Range (ATR) | 2.30 | 0.72 |
| MACD | -0.84 | 0.11 |
| Stochastic Oscillator | 10.22 | 97.48 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Magnolia Oil & Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquids (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area of South Texas, where it targets the Eagle Ford Shale and Austin Chalk formations. It focuses on generating value for shareholders by delivering steady, moderate annual production growth resulting from its capital spending philosophy. The company operates in only one segment and derives the majority of its revenue from the sale of crude oil, natural gas, and natural gas liquids (NGLs).